← Leaderboards
Florent Elefteriou
Vanderbilt University
$11,089,756
Attributed
$11,293,861
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,629,880 · 12
By mechanism
R01$9,575,486 · 6
P01$2,336,019 · 1
R21$1,369,675 · 4
R56$348,700 · 1
Top collaborators
- Jeffry Stephen Nyman2 shared
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionBoneOsteoblastsMouse ModelCellsIn VivoBaseHomeostasisGeneticCell LineageFracturePreventLoss Of FunctionSkeletonMolecularPre-ClinicalAffectPropertyOsteogenesisBone CellDefectPharmaceutical PreparationsIn VitroPathway Interactions
Grant awards (39)
TonEBP/Nfat5, vesicular trafficking and intervertebral disc maintenance$430,111
R01 · FY2025 · AR · contact PI
Etiology of musculoskeletal maladies in NF1$316,800
R01 · FY2025 · AR · contact PI
Characterizing the cell-of-origin for NF1 dystrophic scoliosis$158,400
R21 · FY2025 · AR · contact PI
TonEBP/Nfat5, vesicular trafficking and intervertebral disc maintenance$462,892
R01 · FY2024 · AR · contact PI
Etiology of musculoskeletal maladies in NF1$341,440
R01 · FY2024 · AR · contact PI
Characterizing the cell-of-origin for NF1 dystrophic scoliosis$211,200
R21 · FY2024 · AR · contact PI
Etiology of musculoskeletal maladies in NF1$352,000
R01 · FY2023 · AR · contact PI
Etiology of musculoskeletal maladies in NF1$348,480
R01 · FY2022 · AR · contact PI
Senile Osteoporosis as a Neuroskeletal Disease$396,250
R01 · FY2021 · AG · contact PI
Etiology of musculoskeletal maladies in NF1$352,000
R01 · FY2021 · AR · contact PI
Senile Osteoporosis as a Neuroskeletal Disease$396,250
R01 · FY2020 · AG · contact PI
Senile Osteoporosis as a Neuroskeletal Disease$396,250
R01 · FY2019 · AG · contact PI
Matrix-Sensitive Tools for Detecting NF1-Related Changes in Bone Quality$176,152
R21 · FY2019 · AR
Senile Osteoporosis as a Neuroskeletal Disease$396,250
R01 · FY2018 · AG · contact PI
Matrix-Sensitive Tools for Detecting NF1-Related Changes in Bone Quality$232,059
R21 · FY2018 · AR
Senile Osteoporosis as a Neuroskeletal Disease$396,250
R01 · FY2017 · AG · contact PI
Role of Sympathetic Activation and RANKL/IL6 in Breast Cancer Bone Metastasis$323,700
R01 · FY2017 · CA · contact PI
Role of Sympathetic Activation and RANKL/IL6 in Breast Cancer Bone Metastasis$323,700
R01 · FY2016 · CA · contact PI
Bone pseudarthrosis: from mouse models to pharmacological therapies$348,700
R56 · FY2015 · AR · contact PI
Role of Sympathetic Activation and RANKL/IL6 in Breast Cancer Bone Metastasis$323,700
R01 · FY2015 · CA · contact PI
Role of Sympathetic Activation and RANKL/IL6 in Breast Cancer Bone Metastasis$313,989
R01 · FY2014 · CA · contact PI
Role of Sympathetic Activation and RANKL/IL6 in Breast Cancer Bone Metastasis$323,700
R01 · FY2013 · CA · contact PI
The Norepinephrine Transporter as a Novel Target for a Bone Anabolic Treatment$320,909
R01 · FY2013 · DK · contact PI
Bone Pseudoarthrosis Dissected through the Generation of New Mouse Models$311,832
R01 · FY2013 · AR · contact PI
The Norepinephrine Transporter as a Novel Target for a Bone Anabolic Treatment$332,548
R01 · FY2012 · DK · contact PI
Bone Pseudoarthrosis Dissected through the Generation of New Mouse Models$328,244
R01 · FY2012 · AR · contact PI
The Norepinephrine Transporter as a Novel Target for a Bone Anabolic Treatment$332,371
R01 · FY2011 · DK · contact PI
Bone Pseudoarthrosis Dissected through the Generation of New Mouse Models$328,244
R01 · FY2011 · AR · contact PI
Effect of Tumors on the Skeleton$1,136,863
P01 · FY2010 · CA · contact PI
The Norepinephrine Transporter as a Novel Target for a Bone Anabolic Treatment$368,280
R01 · FY2010 · DK · contact PI
Bone Pseudoarthrosis Dissected through the Generation of New Mouse Models$341,921
R01 · FY2010 · AR · contact PI
Effect of Tumors on the Skeleton$1,141,868
P01 · FY2009 · CA · contact PI
The Norepinephrine Transporter as a Novel Target for a Bone Anabolic Treatment$372,000
R01 · FY2009 · DK · contact PI
Bone Pseudoarthrosis Dissected through the Generation of New Mouse Models$345,375
R01 · FY2009 · AR · contact PI
Effect of Tumors on the Skeleton$57,288
P01 · FY2009 · CA · contact PI
NEUROFIBROMIN (Nf1) SIGNALING AND TARGET GENES IN OSTEOBLASTS$149,049
R21 · FY2007 · AR · contact PI
Glucocorticoid-induced bone loss via Beta2-adrenergic signaling in osteoblasts$148,927
R21 · FY2007 · DK · contact PI
NEUROFIBROMIN (Nf1) SIGNALING AND TARGET GENES IN OSTEOBLASTS$149,368
R21 · FY2006 · AR · contact PI
Glucocorticoid-induced bone loss via Beta2-adrenergic signaling in osteoblasts$144,520
R21 · FY2006 · DK · contact PI